JohnsonLEARNING OBJECTIVES:At the conclusion of this activity, participants will be able to:1. Integrate immunotherapy and targeted therapy into the multimodal management of MIBC, selecting appropriate regimens and sequencing strategies based on current guidelines, clinical trial data, and patient-specific factors.2. Evaluate the clinical role, mechanisms of action, and evidence base for targeted therapies in MIBC, including biomarker-driven selection to support personalized treatment planning.3. Develop and apply practical approaches for preventing, monitoring, and managing immune-related adverse events and other toxicities associated with immunotherapy and targeted therapy to optimize patient safety, adherence, and quality of life.